<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05100784</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01972-37</org_study_id>
    <nct_id>NCT05100784</nct_id>
  </id_info>
  <brief_title>The Human Sperm Survival Assay (HSSA) as an Internal Quality Control for the IVF Consumables (REPROTOX 2)</brief_title>
  <acronym>REPROTOX 2</acronym>
  <official_title>The Human Sperm Survival Assay (HSSA) as an Internal Quality Control for the IVF Consumables</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Clinical Trial Experts Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Private hospital Parly II</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main embryotoxicity quality controls are the mouse embryo test (MEA = Mouse Embryo Assay)&#xD;
      and the human sperm survival test (HSSA = Human Sperm Survival Assay). The HSSA test measures&#xD;
      the survival (or mobility) of human sperm after exposure to the tested consumable for a&#xD;
      predetermined period of time and compares it to that of unexposed sperm. It would appear that&#xD;
      the HSSA is comparable in terms of sensitivity to the MEA test for the detection of toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to assess the embryotoxicity of the main IVF consumables using the HSSA&#xD;
      test before their introduction to the IVF laboratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">March 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of embryotoxicity</measure>
    <time_frame>1 day</time_frame>
    <description>Presence of embryotoxicity, defined by a mobility index relative to the control (SMI) &lt;0.85 observed on at least 2 of the three tests carried out on consumables from the same batch (isolated embryotoxicity).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Human Sperm Survival Assay</condition>
  <condition>Embryotoxicity</condition>
  <condition>in Vitro Fertilization</condition>
  <arm_group>
    <arm_group_label>Sperm with normal spermogramm and more than 10 millions spermatozoids</arm_group_label>
    <description>Normal spermogramm : concentration ≥15 million / ml or total count&gt; 39 million, progressive mobility ≥32% or total mobility ≥40%</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSSA test</intervention_name>
    <description>Human Sperm Survival Assay testing performed on different batches of different types of IVF consumables. In practice, 3 consumables from the same batch will be tested with 3 different sperms to ensure the repeatability of the result / test.</description>
    <arm_group_label>Sperm with normal spermogramm and more than 10 millions spermatozoids</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male between 18 and 65 years-old with normal spermogram&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male over 18 years-old&#xD;
&#xD;
          -  Normal spermogram (concentration ≥15 million / ml or total count&gt; 39 million,&#xD;
             progressive mobility ≥32% or total mobility ≥40%)&#xD;
&#xD;
          -  Progressive mobility ≥70% after selection&#xD;
&#xD;
          -  Total number of progressive motile spermatozoa recovered after TMS&gt; 10 million&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme&#xD;
&#xD;
          -  Patient having been informed and not opposing to this research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male over 65 years-old&#xD;
&#xD;
          -  Protected patient: adult under guardianship, curatorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>0683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Private Hospital of Parly II-Le Chesnay</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Oudet</last_name>
      <phone>0683346567</phone>
      <email>jf.oudet@ecten.eu</email>
    </contact>
    <contact_backup>
      <last_name>Marie-Hélène Barba</last_name>
      <email>mh.barba@ecten.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

